Do novel pharmacological therapies (Zilebesiran, lorundrostat, baxdrostat) lower blood pressure and improve outcomes in patients with hypertension?
Patients with hypertension (HTN)
Novel pharmacological therapies (Zilebesiran, lorundrostat, baxdrostat)
Blood pressure lowering and improvement in cardiovascular and renal outcomes
Novel therapies such as Zilebesiran, lorundrostat, and baxdrostat show significant potential for hypertension management, highlighting future challenges in reimbursement and healthcare implementation once licensed.
Novel therapies (Zilebesiran, lorundrostat, baxdrostat) have shown great potential in lowering BP that is clinically meaningful to help improve cardiovascular and renal outcomes. ASI therapies lorundrostat and baxdrostat are close to being licensed for HTN. Once commercially available and recommended in treatment guidelines, the next big challenge will be reimbursement and implementation model in different healthcare systems.
Building similarity graph...
Analyzing shared references across papers
Loading...
Manish Saxena
UCL Biomedical Research Centre
Feng J. He
Preventive Cardiology
Fotios Drenos
Brunel University of London
Current Opinion in Nephrology & Hypertension
Queen Mary University of London
UCL Biomedical Research Centre
Building similarity graph...
Analyzing shared references across papers
Loading...
Saxena et al. (Fri,) studied this question.
synapsesocial.com/papers/69a75cd6c6e9836116a26079 — DOI: https://doi.org/10.1097/mnh.0000000000001163